RxDoctor Payments DataLook up a doctor →

Eranga Haththotuwa, MD

Cardiovascular Disease · Dover, DENPI 1669477618

Payments from drug & device makers

$14,925in general payments, 2019–2025

Across 770 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$2K
  • Amgen$2K
  • Medtronic$2K
  • AstraZeneca$1K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $6K from 32 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Actelion Pharmaceuticals US, Inc.73$2,134
Amgen84$1,593
Medtronic(2 entities)75$1,592
AstraZeneca61$1,164
Novartis70$1,051
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)52$1,017
Pfizer55$903
Boehringer Ingelheim46$840
Bayer33$715
Johnson & Johnson37$552
Abbott25$512
E.r. Squibb & Sons, L.L.C.33$456
Esperion Therapeutics, Inc.26$447
Merck17$339
Regeneron Healthcare Solutions, Inc.13$233
Boston Scientific9$188
Amarin Pharma, Inc.9$137
Sanofi-aventis U.S. LLC7$119
Kiniksa Pharmaceuticals, Ltd.6$115
Novo Nordisk5$102
Baxter Healthcare1$90
Alnylam Pharmaceuticals Inc.3$73
Bridgebio Pharma, Inc.4$73
Medicomp Inc2$51
Tactile Systems Technology Inc3$51
Lundbeck LLC3$45
Lexicon Pharmaceuticals, Inc.2$40
Philips North America LLC2$39
Amryt Pharma Holdings Ltd2$37
Kowa Pharmaceuticals America, Inc.2$33
Chiesi USA, Inc.2$32
G Medical Diagnostic Services, Inc.2$32
Abiomed1$25
Cardiovascular Systems Inc.1$25
Heartflow, Inc.1$19
Kiniksa Pharmaceuticals International, PLC1$19
Daiichi Sankyo Inc.1$18
Aegerion Pharmaceuticals, Inc.1$12

How this compares

$14,925 in reported general payments places this provider in the 75th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware →

Medicare billing

Part B allowed, 2024
$776,516
Medicare patients
2,374
Services billed
10,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Dover

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →